Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2025

Oct 4, 2025

33148_dirs_2025-10-03_8c2a2844-c6ab-4152-ac96-909879072cb9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2025-09-24

Reporting Person: Fong Peter (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-09-24 Common Stock A 23333 Acquired 23333 Direct
2025-09-24 Common Stock A 30000 Acquired 53333 Direct

Footnotes

F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on September 24, 2026.

F2: Represents RSUs that will vest in equal monthly installments over a three-year period following September 23, 2025.